Stimulation of intestinal growth and function with DPP-IV inhibition in a mouse short 1 bowel syndrome model 2 3

32 Glucagon-like peptide-2 (GLP-2) has been shown to be effective in patients with short bowel syndrome 33 (SBS), but is rapidly inactivated by dipeptidyl peptidase-IV (DPP4). We used an orally-active DPP4 inhibitor 34 (DPP4-I), MK-0626, to determine the efficacy of this approach to promote adaptation after SBS, determined 35 optimal dosing, and identified… CONTINUE READING